Compare Pfizer Inc (PFE) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Atlassian Corporation PLC — how do they compare? Pfizer Inc trades at $24.94 (market cap $142.14B), while Atlassian Corporation PLC trades at $85.86 (market cap $22.99B). The key difference: Pfizer Inc is far larger — about 6.2× Atlassian Corporation PLC's market cap, and Pfizer Inc pays a 6.9% dividend while Atlassian Corporation PLC pays none. Which is the better fit depends on your goals.
| PFE | TEAM | |
|---|---|---|
Market Cap | $142.14B | $22.99B |
Volume | 29,869,932 | — |
Sector | Health | Technology |
52-Week High | $28.56 | $203.00 |
52-Week Low | $23.29 | $57.15 |
Enterprise Value | $192.80B | $23.10B |
Dividend Yield | 6.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
Atlassian (TEAM) trades at $90.60, down 2.88% on the day, with a bullish technical signal from moving averages and strong analyst support (67% buy ratings). The company shows accelerating revenue growth, reaching $5.22B in 2025, and has beaten earnings estimates for three consecutive quarters. Recent news highlights AI-driven product enhancements and enterprise adoption momentum, with the Service Collection surpassing $1B in annual recurring revenue.
TEAM presents a growth investment case with a consensus price target of $114.54 (26% upside), supported by cloud momentum and AI integration. However, persistent net losses (-$256.69M in 2025) and high valuation multiples (P/S 3.96, P/B 26.93) pose risks amid competitive pressures and macroeconomic sensitivity in software spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
